Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nanobiotix S.A. ADR
(NQ:
NBTX
)
7.230
-0.030 (-0.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nanobiotix S.A. ADR
< Previous
1
2
3
4
Next >
Voting Rights and Shares Capital of the Company
May 16, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
May 15, 2024
Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
May 14, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
April 24, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
April 17, 2024
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
April 10, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
April 02, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Present at Upcoming Investor Conferences in March
March 06, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
February 13, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
January 31, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
January 29, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
January 11, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
December 26, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
December 13, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
December 04, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
November 13, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
November 09, 2023
Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
November 08, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Closing of Global Offering
November 07, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
November 02, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
November 01, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
October 23, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
October 11, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
September 29, 2023
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1
October 04, 2023
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society...
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
September 28, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
September 26, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
September 19, 2023
Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
September 13, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
September 05, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.